Limitations of A1c Testing for Patients with Hemoglobin Variants

Understanding the Hemoglobin A1c Test and Its Role in Diabetes Management

The Hemoglobin A1c (HbA1c) test has become a cornerstone of diabetes care, providing healthcare professionals with a reliable measure of long-term blood glucose control. This test provides an average measure of glucose control for the long-term (8–12 weeks), making it far more informative than single-point glucose measurements that can fluctuate throughout the day based on meals, physical activity, and stress levels.

HbA1c results from glycation at the N-terminus of the β globin chain of tetrameric human hemoglobin. This biochemical process occurs when glucose molecules in the bloodstream bind to hemoglobin proteins within red blood cells. Because red blood cells typically survive for approximately 120 days, the HbA1c measurement reflects the average blood glucose concentration over the preceding two to three months.

The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated conclusively that risks for complications are related directly to glycemic control, as measured by HbA1c. These landmark studies established HbA1c as the gold standard for assessing diabetes management and predicting the risk of developing serious complications such as retinopathy, nephropathy, and cardiovascular disease.

The National Glycohemoglobin Standardization Program (NGSP) was established to ensure that HbA1c measurements across different laboratories and testing methods remain comparable and traceable to the standards used in these pivotal clinical trials. This standardization has been crucial for maintaining consistency in diabetes care and treatment decisions worldwide.

What Are Hemoglobin Variants?

Hemoglobin variants, also known as hemoglobinopathies, are genetic differences in the structure of hemoglobin—the oxygen-carrying protein found in red blood cells. Normal adult human hemoglobin is a tetrameric protein consisting of α and β globin chains in duplicate, HbA (α2β2). The point mutation in the globin chain results in genetic variants of human hemoglobin such as HbS, HbD, HbE, HbJ, etc.

Normal human hemoglobin is made up of about 98% hemoglobin A (HbA). Some people have both HbA and another kind of Hb, such as hemoglobin S, C, D or E. These less common forms of hemoglobin are called hemoglobin variants, or hemoglobinopathies. These genetic variations occur when a single amino acid substitution changes the structure of the hemoglobin molecule.

The most common Hb variants worldwide are HbS, HbE, HbC, and HbD. All of these Hb variants have single amino acid substitutions in the Hb β chain. The prevalence of these variants varies significantly across different populations and geographic regions.

Geographic Distribution and Prevalence

Some hemoglobin variants are more common in different races, and in different parts of the world. For instance, a person might be more likely to have one of these Hb variants if they are of African, Mediterranean, or Asian heritage. Understanding these population-specific patterns is essential for healthcare providers serving diverse communities.

About 8 percent of African American babies are born with sickle cell trait, making it one of the most common hemoglobin variants in the United States. An estimated 10%-30% of the population in West and Central Africa carry the hemoglobin S (HbS) allele, highlighting the significant prevalence of this variant in certain populations.

Hemoglobin E is particularly prevalent among people of Southeast Asian descent, while hemoglobin C is found primarily in individuals of West African ancestry. These variants evolved in regions where malaria was endemic, as carriers of certain hemoglobin variants have some protection against severe malaria infection.

Heterozygous vs. Homozygous States

Individuals can inherit hemoglobin variants in different patterns. Heterozygous individuals have a condition such as hemoglobin AS (HbAS). These patients inherited a copy of the variant gene from one parent and may be referred to as "carriers" or as having the sickle cell "trait." These patients are usually asymptomatic.

Homozygous individuals have a condition such as hemoglobin SS (HbSS). These patients have a copy of the variant gene from each parent and have sickle cell disease. Homozygous states typically result in more severe clinical manifestations, including chronic hemolytic anemia and various complications.

Compound heterozygous individuals have a condition such as hemoglobin SC (HbSC). These patients have inherited genes for two hemoglobin variant genes—HbS from one parent and HbC from the other—and may have less severe sickle cell symptoms.

Most people don't know that they have a hemoglobin variant, particularly those who are heterozygous carriers without symptoms. This lack of awareness can lead to unexpected complications when undergoing HbA1c testing for diabetes management.

How Hemoglobin Variants Interfere with A1c Testing

In people who have hemoglobin variants such as HbS (sickle cell trait), some A1C tests give falsely high or low readings that can lead to the over-treatment or under-treatment of diabetes. The mechanisms behind this interference are complex and vary depending on both the specific hemoglobin variant and the testing method employed.

Mechanisms of Interference

Hemoglobinopathies can affect HbA1c values in 3 ways: by influencing the binding of glucose to Hb, affecting chromatography peak measurements, and increasing the risk of hemolysis and hence decreasing the life span of red blood cells. Each of these mechanisms can independently or collectively compromise the accuracy of HbA1c measurements.

Genetic variants of hemoglobin may interfere with HbA1c quantification using ion exchange chromatography, capillary electrophoresis, immunoassay and boronate affinity chromatography. This widespread interference across multiple testing platforms underscores the pervasive nature of the problem.

When using high-performance liquid chromatography (HPLC) methods, variants that elute with the hemoglobin A1c peak will cause a falsely high hemoglobin A1c result. Conversely, some variants may elute separately, potentially causing falsely low readings or making accurate quantification impossible.

Red Blood Cell Lifespan Effects

One of the most significant factors affecting HbA1c accuracy in patients with hemoglobin variants is altered red blood cell survival. If the hemoglobin variant of the trait endows red blood cells with a shorter lifespan, the cells' hemoglobin would carry less accumulated blood glucose, leading to falsely low HbA1c readings.

In iron deficiency anemia and folate or B12 anemias, for instance, RBC lifespan is increased, and that can cause a falsely elevated HbA1c result. Conversely, clinical scenarios that lead to decreased red blood cell survival—chronic blood loss, hemolytic anemia, or pregnancy, for example—can lead to falsely decreased levels of hemoglobin A1c.

In SCD, hemoglobin polymerizes under deoxygenated conditions, causing red blood cells to assume a sickled shape. These abnormally shaped cells are prone to hemolysis and have a significantly shortened lifespan, leading to chronic hemolytic anemia and vaso-occlusive complications. Even in the absence of acute sickle cell crises, patients with SCD may experience subclinical hemolysis and baseline anemia, which can interfere with diagnostic tools that rely on red blood cell survival.

Method-Specific Interference Patterns

Laboratories use many different methods for measuring A1C, but some of these methods can give inaccurate results when the patient has a hemoglobin variant such as sickle cell trait or if there is an elevated level of fetal hemoglobin (HbF). The degree of interference varies considerably depending on the specific assay methodology.

Research has examined effects of hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by twelve methods, revealing significant variability in how different testing platforms handle these variants. While most of the methods evaluated did not show clinically significant interference with HbA1c results in the presence of the tested variants, the Roche b 101 POC method showed a clinically significant differences for HbAC and HbAE. Although the bias for HbAC was only marginally clinically significant at 9% HbA1c, the biases for HbAE were >10% at both 6 and 9% HbA1c, respectively.

The criteria used to determine whether or not a method shows interference that is clinically significant (indicated by "Yes") is >±6% at 6 and/or 9% A1C. This threshold helps laboratories and clinicians identify when interference may lead to clinically meaningful errors in diabetes management.

Clinical Evidence of A1c Inaccuracy in Hemoglobin Variant Carriers

Multiple clinical studies have documented the real-world impact of hemoglobin variants on HbA1c testing accuracy, with potentially serious implications for patient care.

Sickle Cell Trait and A1c Underestimation

In a retrospective study of 4,620 African-Americans from two established cohorts, investigators compared HbA1c results between patients with and without sickle cell trait. They discovered that among those with the trait, the mean HbA1c was 5.7 percent, compared to 6.0 in those without — even though the two groups showed similar blood glucose levels through other tests.

Using standard clinical HbA1c cutoffs resulted in identifying 40 percent fewer potential cases of prediabetes and 48 percent fewer potential cases of diabetes in people with SCT than in people without SCT. This dramatic underdiagnosis represents a significant public health concern, particularly given the high prevalence of sickle cell trait in certain populations.

The test may be underestimating long-term glucose levels in patients with sickle cell trait, and lead to missed opportunities for diabetes diagnosis and intervention. Early detection and treatment of diabetes are crucial for preventing complications, making this underestimation particularly problematic.

Hemoglobin C Trait and A1c Overestimation

While sickle cell trait tends to cause falsely low HbA1c readings, hemoglobin C trait can have the opposite effect. The DCA 2000 HbA1c immunoassay method showed significant positive bias in patients with HbC trait. One possible clinical implication of this overestimation is overly rigorous glycemic control with a concomitant increase in hypoglycemia.

This overestimation could lead to overly rigorous glycemic control with a concomitant increase in hypoglycemia. This may be especially important in certain ethnic populations, such as African-Americans, who have a relatively high prevalence of HbC trait. Hypoglycemia can be dangerous, causing symptoms ranging from confusion and dizziness to loss of consciousness and seizures in severe cases.

Case Reports Illustrating Clinical Impact

Individual case reports provide compelling evidence of how hemoglobin variants can lead to diagnostic confusion and inappropriate treatment. Sickle cell disease (SCD) and alpha thalassemia are inherited disorders characterized by chronic anemia and altered red blood cell turnover, both of which can significantly interfere with the accuracy of HbA1c measurements. In such cases, HbA1c may appear falsely low, potentially delaying the diagnosis and treatment of diabetes mellitus. A 63-year-old female with previously undiagnosed SCD and alpha thalassemia had longstanding hyperglycemia and diabetic complications that were masked by inappropriately low HbA1c values.

Another documented case involved a patient whose HbA1c measured 10.1% by immunoassay, despite normal fasting glucose levels. The patient was started on diabetes medications based on the elevated HbA1c, but subsequent glucose monitoring showed excellent glycemic control. This discrepancy persisted for years before the underlying hemoglobin variant was identified, illustrating how interference can lead to years of unnecessary treatment.

Using a method where you can't identify or know that the patient has a hemoglobin variant could lead to delayed diabetes diagnosis, as demonstrated in multiple clinical scenarios. The inability to detect variants during routine HbA1c testing compounds the problem, as clinicians may not suspect interference without additional clues.

Clinical Consequences of Inaccurate A1c Results

The interference of hemoglobin variants with HbA1c testing has far-reaching implications for patient care, affecting both diagnosis and ongoing management of diabetes.

Misdiagnosis and Delayed Diagnosis

With some assay methods, A1C tests in patients with hemoglobinopathies result in falsely high outcomes, overestimating actual average blood glucose levels for the previous 3 months. Health care professionals might falsely diagnose patients or prescribe more aggressive treatments, resulting in increased episodes of hypoglycemia.

Conversely, some assay methods used with certain hemoglobinopathies may result in falsely low outcomes, leading to undertreatment of diabetes. Undertreatment allows chronic hyperglycemia to persist, accelerating the development of microvascular and macrovascular complications including retinopathy, nephropathy, neuropathy, and cardiovascular disease.

Clinicians need to be aware that among individuals with sickle cell trait, the use of HbA1c to screen for diabetes or pre-diabetes may be inaccurate. This awareness is particularly critical in primary care settings where initial diabetes screening often occurs.

Inappropriate Treatment Intensification or De-escalation

When HbA1c results do not accurately reflect glycemic control, treatment decisions based on these values can be harmful. Falsely elevated HbA1c may prompt clinicians to intensify diabetes therapy unnecessarily, increasing medication doses or adding additional agents. This aggressive approach increases the risk of hypoglycemia, which can be particularly dangerous for elderly patients, those with cardiovascular disease, or individuals with hypoglycemia unawareness.

Conversely, falsely low HbA1c values may lead to inappropriate de-escalation of therapy or failure to intensify treatment when needed. Patients may continue with inadequate glycemic control for months or years, accumulating damage to blood vessels, nerves, and organs that could have been prevented with appropriate treatment.

Impact on Clinical Trial Enrollment and Research

Inaccurate HbA1c measurements in patients with hemoglobin variants can also affect clinical research. Patients may be inappropriately included or excluded from clinical trials based on erroneous HbA1c values, potentially skewing study results and limiting the generalizability of findings to diverse populations.

Additionally, the systematic underestimation or overestimation of HbA1c in certain ethnic groups could contribute to health disparities if not properly recognized and addressed. Research outcomes may not accurately reflect the true burden of diabetes or the effectiveness of interventions in populations with high prevalence of hemoglobin variants.

Identifying Patients at Risk for A1c Interference

Healthcare providers must be vigilant in identifying patients who may be at risk for inaccurate HbA1c results due to hemoglobin variants or other interfering conditions.

Clinical Red Flags

Any time there is a discrepancy between an A1C result and the clinical impression based on other tests, health care professionals should verify the accuracy of the results. Key warning signs include:

• HbA1c results that are inconsistent with self-monitored blood glucose readings
• HbA1c values that don't correlate with fasting plasma glucose or oral glucose tolerance test results
• Unexplained changes in HbA1c that don't correspond to changes in diabetes management
• Symptoms of hyperglycemia or hypoglycemia that don't match HbA1c values
• Known history of anemia or hemoglobin disorders

If the physician sees something that doesn't make sense, they shouldn't take the A1c value at face value—there should be conversations about what might be happening. Open communication between laboratory professionals and clinicians is essential for identifying and resolving discrepancies.

Population-Based Risk Assessment

Certain populations have higher prevalence of hemoglobin variants and warrant increased vigilance. Healthcare providers should consider hemoglobin variant screening for patients of African, Mediterranean, Middle Eastern, or Southeast Asian ancestry, particularly when initiating diabetes monitoring or when HbA1c results seem inconsistent with clinical presentation.

Not many people with sickle cell trait in the United States know they carry the variant, especially those born before routine screenings at birth began. This lack of awareness means that many adults with hemoglobin variants remain undiagnosed, making proactive screening particularly important.

Laboratory Testing Strategies

If a health care professional suspects that a patient may have a hemoglobinopathy, the patient's carrier status can be detected using hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), or isoelectric focusing. These tests can identify the presence and type of hemoglobin variants, allowing for appropriate interpretation of HbA1c results.

The test should be performed by an HPLC or capillary electrophoresis method that does not demonstrate analytical interference from the Hb variants or that can presumptively detect a Hb variant. Some modern HbA1c testing platforms can simultaneously measure HbA1c and detect common hemoglobin variants, providing valuable information in a single test.

Doctors or patients interested in getting information about the accuracy of a particular A1C method for patients with hemoglobin variants should first find out which method your laboratory is using. If your diabetes patient has a hemoglobin variant, your lab should use a method that does not show interference from that variant in order to produce an accurate A1C result.

Alternative Testing Methods for Patients with Hemoglobin Variants

When HbA1c testing is unreliable due to hemoglobin variants or other interfering conditions, several alternative methods can provide accurate assessment of glycemic control.

Fructosamine Testing

Fructosamine is a glycated protein that reflects average blood glucose levels over the preceding two to three weeks. Unlike HbA1c, fructosamine measurement is not affected by hemoglobin variants because it measures glycation of serum proteins, primarily albumin, rather than hemoglobin.

Serum fructosamine was established as a potential glycemic biomarker that is not affected by abnormal hemoglobin. Serum fructosamine was similar between individuals with or without sickle cell trait (median: 287 vs 275 umol/L, p = 0·11, respectively) despite statistically different HbA1c. Serum fructosamine is a good alternative to HbA1c for monitoring and diagnosing T2D in the presence of sickle cell trait.

Fructosamine levels were determined in place of HbA1c levels when unstable Hb variants were identified, demonstrating its practical utility in clinical settings. However, fructosamine has some limitations, including shorter time frame of glycemic assessment and potential interference from conditions affecting serum protein levels, such as nephrotic syndrome or severe liver disease.

Glycated Albumin

Glycated albumin is another alternative marker that measures the percentage of albumin that has been glycated. Like fructosamine, it reflects glycemic control over a shorter period (approximately two to three weeks) and is not affected by hemoglobin variants or red blood cell turnover.

Glycated albumin may be particularly useful in patients with conditions that affect red blood cell lifespan, including not only hemoglobin variants but also chronic kidney disease, liver cirrhosis, and pregnancy. Some studies suggest that glycated albumin may be superior to HbA1c for predicting postprandial hyperglycemia and glycemic variability.

Continuous Glucose Monitoring

Continuous glucose monitoring (CGM) systems provide real-time glucose measurements throughout the day and night, offering detailed information about glucose patterns, variability, and time spent in target range. CGM data can be used to calculate glucose management indicator (GMI), a metric that estimates what the HbA1c would be based on average glucose levels.

For patients with hemoglobin variants, CGM offers several advantages. It provides direct measurement of glucose levels without reliance on glycated proteins, eliminates interference from hemoglobin variants, and offers insights into glucose variability that HbA1c cannot capture. The time in range metric from CGM has emerged as a valuable complement or alternative to HbA1c for assessing glycemic control.

However, CGM requires patient commitment to wearing the device, can be expensive, and may not be covered by all insurance plans. Additionally, accuracy can be affected by factors such as sensor placement, calibration, and individual physiological variations.

Self-Monitoring of Blood Glucose

Traditional self-monitoring of blood glucose (SMBG) using fingerstick testing remains a valuable tool, particularly when HbA1c results are questionable. While SMBG provides only point-in-time measurements rather than an integrated assessment of glycemic control, systematic testing at various times (fasting, pre-meal, post-meal, and bedtime) can provide a comprehensive picture of glucose patterns.

SMBG is widely available, relatively inexpensive, and provides immediate feedback that patients can use to adjust diet, exercise, and medication. When HbA1c is unreliable, more frequent SMBG may be necessary to guide treatment decisions and assess the effectiveness of interventions.

Fasting Plasma Glucose and Oral Glucose Tolerance Testing

Fasting plasma glucose (FPG) and oral glucose tolerance tests (OGTT) measure glucose levels directly and are not affected by hemoglobin variants. These tests can be used for both diagnosis and monitoring of diabetes when HbA1c is unreliable.

When the authors used other blood glucose measures as the diagnostic criteria, they found no significant difference in the likelihood of diabetes and prediabetes among patients with or without SCT, demonstrating that these alternative tests provide accurate assessment regardless of hemoglobin variant status.

However, these tests have limitations including greater day-to-day variability, inconvenience of fasting requirements, and the fact that they represent only a single point in time rather than long-term glycemic control. The OGTT in particular is time-consuming and may be poorly tolerated by some patients.

Mass Spectrometry-Based Methods

Mass spectrometry measures total glycation of hemoglobin across both α and β globin chains and correlates well with the ion exchange based method. Additionally, mass spectrometry based quantification is not impacted by the presence of genetic variants of hemoglobin and thus might be a better analytical choice for diabetes mellitus.

Mass spectrometry offers high specificity and accuracy, directly measuring glycated hemoglobin without interference from variants. However, this technology is expensive, requires specialized equipment and expertise, and is not widely available in routine clinical laboratories. As the technology becomes more accessible and cost-effective, it may become a more practical option for patients with hemoglobin variants.

Selecting Appropriate A1c Testing Methods

Not all HbA1c testing methods are equally affected by hemoglobin variants. Understanding the strengths and limitations of different methodologies can help laboratories and clinicians select the most appropriate testing approach for their patient populations.

High-Performance Liquid Chromatography (HPLC)

Cation-exchange high-performance liquid chromatography (HPLC), which was used in the Diabetes Control and Complications Trial, is the second most common method in use today. It works by applying buffers of increasing ionic strength to the cation-exchange column, which then elutes the different Hb species at separate times. The concentration is measured after elution from the column and that's used to quantify the percent of hemoglobin A1c by calculating the area under each peak from the ion-exchange chromatography.

HPLC methods have the advantage of being able to detect hemoglobin variants based on their elution patterns, potentially alerting clinicians to the presence of variants that might interfere with results. HPLC provided more information about the presence of Hb-Vars than enzymatic assays.

However, variant hemoglobins will affect the results in a variety of ways. Some variants elute separately and don't interfere, while others co-elute with HbA1c or HbA0, causing inaccurate results. The specific interference pattern depends on both the variant and the particular HPLC system used.

Immunoassay Methods

Immunoassay methods use antibodies that specifically recognize glycated amino acids at the N-terminus of the beta chain of hemoglobin. Immunoassay methods do not have clinically significant interference from HbE and HbD because the E and D substitution are distant from the N-terminus of the hemoglobin beta chain.

This selectivity can be advantageous for certain variants, but immunoassays are not immune to all interference. It can generally be assumed that immunoassay, boronate affinity and enzymatic methods show interference from elevated HbF levels. Additionally, some immunoassays show significant interference from HbS and HbC variants.

Enzymatic Methods

Enzymatic methods measure HbA1c using specific enzymes that cleave or react with glycated hemoglobin. These methods can be automated and offer rapid turnaround times. However, using the Abbott HbA1c assay in the presence of certain hemoglobin variants can induce clinically relevant interference that can affect diagnosis and therapy monitoring decisions, mainly because the enzymatic assay cannot provide any information about Hb variants.

The inability of enzymatic methods to detect hemoglobin variants is a significant limitation, as clinicians may not be alerted to potential interference. This makes enzymatic methods less suitable for populations with high prevalence of hemoglobin variants unless used in conjunction with separate variant screening.

Boronate Affinity Chromatography

Boronate affinity methods separate glycated from non-glycated hemoglobin based on the binding of cis-diol groups of glycated hemoglobin to boronic acid. These methods are generally less affected by hemoglobin variants that don't alter the glycation sites, but they can be affected by other glycated proteins and elevated HbF.

Capillary Electrophoresis

Capillary electrophoresis separates hemoglobin species based on their charge-to-mass ratio in an electric field. Like HPLC, capillary electrophoresis can detect hemoglobin variants, but interference patterns vary depending on the specific variant and its electrophoretic mobility relative to HbA1c.

Point-of-Care Testing

Point-of-care (POC) HbA1c testing offers the convenience of immediate results during a clinical visit, facilitating real-time treatment decisions. However, POC methods vary in their susceptibility to interference from hemoglobin variants. Some POC devices use immunoassay technology, while others employ boronate affinity or enzymatic methods.

The convenience of POC testing must be balanced against the potential for inaccuracy in patients with hemoglobin variants. Healthcare providers using POC testing should be aware of the specific method's limitations and consider confirmatory testing with alternative methods when results are inconsistent with clinical presentation.

Laboratory and Clinical Practice Recommendations

Addressing the challenges posed by hemoglobin variants requires coordinated efforts from laboratories, clinicians, and healthcare systems.

Laboratory Best Practices

Laboratories should carefully select HbA1c methods appropriate for their patient populations. In areas with high prevalence of hemoglobin variants, methods that can detect variants or show minimal interference should be prioritized. Genetic variants (e.g. HbS trait, HbC trait), elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements. The effects vary depending on the specific Hb variant or derivative and the specific HbA1c method.

When hemoglobin variants are detected during HbA1c testing, laboratories should clearly communicate this information to ordering providers. If a potential interference is detected, the hemoglobin A1c result should not be reported, and a potential interference should be noted. Consultation by the provider with the laboratory medical director or a pathologist also is recommended.

Laboratories should maintain up-to-date information about their HbA1c method's performance with common hemoglobin variants and make this information readily available to clinicians. The NGSP website provides comprehensive information about method-specific interferences that laboratories can reference.

Clinical Decision-Making Strategies

Clinicians should maintain a high index of suspicion for HbA1c interference in patients from populations with high prevalence of hemoglobin variants. When initiating diabetes monitoring, consider baseline hemoglobin variant screening for at-risk patients.

Always correlate HbA1c results with other measures of glycemic control, including fasting glucose, postprandial glucose, and patient-reported symptoms. Significant discrepancies should prompt investigation for potential interference.

Since the measurement of HbA1c is dependent on a normal erythrocyte life span, it is recommended that other tests be used to estimate glycemic control in those with sickle cell, HbC, or HbD disease. Because erythrocyte survival is normal in those with heterozygous variants, HbA1c can be used as long as the Hb variant does not interfere either with the assay method itself or with glucose binding to Hb.

For patients with known hemoglobin variants, establish a monitoring strategy using alternative methods or HbA1c methods known not to show interference with that specific variant. Document the patient's variant status prominently in the medical record to ensure all providers are aware of potential testing limitations.

Patient Education and Engagement

Patients with hemoglobin variants should be educated about potential limitations of HbA1c testing and the importance of using alternative monitoring methods. They should understand that their HbA1c results may not accurately reflect their glucose control and should not be the sole basis for treatment decisions.

Encourage patients to maintain detailed records of self-monitored blood glucose readings and to report any symptoms of hyperglycemia or hypoglycemia, even if HbA1c results appear to be in target range. Patients should be empowered to question discrepancies between their HbA1c results and their day-to-day glucose readings or symptoms.

Healthcare System Considerations

Healthcare systems should develop protocols for identifying and managing patients with hemoglobin variants. Electronic health record systems can be configured to flag patients with known variants and alert providers to potential HbA1c interference.

Insurance coverage for alternative testing methods should be ensured for patients with documented hemoglobin variants or other conditions that interfere with HbA1c testing. This includes coverage for more frequent SMBG supplies, CGM systems, or alternative biomarkers such as fructosamine or glycated albumin.

Quality improvement initiatives should monitor for potential systematic bias in diabetes care for populations with high prevalence of hemoglobin variants, ensuring that these patients receive appropriate diagnosis and treatment despite testing challenges.

Future Directions and Emerging Technologies

Ongoing research and technological development continue to address the challenges of glycemic monitoring in patients with hemoglobin variants.

Improved Testing Methods

Manufacturers continue to refine HbA1c testing methods to minimize interference from hemoglobin variants. Manufacturers are doing a great job of developing methods that aren't susceptible to analytical interferences from these variants. Newer generations of testing platforms show improved performance with common variants, though no method is completely immune to all interference.

Software updates and algorithm improvements can sometimes resolve interference issues without requiring new hardware. Common Hb-variants show no longer interference on the Tosoh G8 after an update of the software. Software updates of Tosoh HPLC analyzers can cause and resolve interference of Hb-variants for HbA1c.

Expanded Use of Mass Spectrometry

As mass spectrometry technology becomes more accessible and affordable, it may become a more practical option for routine HbA1c testing, particularly in populations with high prevalence of hemoglobin variants. Mass spectrometry's ability to accurately measure glycated hemoglobin regardless of variant status makes it an ideal solution, though current cost and complexity limit widespread adoption.

Integration of Multiple Biomarkers

Future diabetes management may rely less on a single biomarker and more on integration of multiple measures of glycemic control. Combining HbA1c (when reliable) with CGM-derived metrics, glycated albumin, and traditional glucose measurements may provide a more comprehensive and accurate assessment of diabetes control.

Artificial intelligence and machine learning algorithms could potentially integrate data from multiple sources to provide personalized glycemic assessments that account for individual factors including hemoglobin variants, red blood cell turnover, and other variables affecting traditional biomarkers.

Personalized Medicine Approaches

As genetic testing becomes more routine, hemoglobin variant status may be incorporated into electronic health records from birth or early childhood, allowing for proactive selection of appropriate monitoring strategies throughout life. Pharmacogenomic data could be integrated with glycemic monitoring to optimize both testing and treatment approaches for individual patients.

Global Health Implications

The intersection of diabetes and hemoglobin variants is particularly relevant in regions where both conditions are highly prevalent, including sub-Saharan Africa, the Middle East, and parts of Asia. Developing cost-effective, accurate monitoring strategies for these populations is a global health priority.

Research into alternative biomarkers that are both accurate in the presence of hemoglobin variants and feasible for resource-limited settings could have significant impact on diabetes care in low- and middle-income countries. Point-of-care technologies that can simultaneously detect hemoglobin variants and provide accurate glycemic assessment would be particularly valuable.

Special Populations and Considerations

Pregnancy and Gestational Diabetes

Pregnancy presents unique challenges for glycemic monitoring, as HbA1c can be affected by increased red blood cell turnover, hemodilution, and iron deficiency in addition to any hemoglobin variants. For pregnant women with hemoglobin variants, HbA1c becomes even less reliable, making alternative monitoring methods essential.

Gestational diabetes screening and management in women with hemoglobin variants should rely primarily on glucose-based testing (fasting glucose, glucose challenge test, oral glucose tolerance test) rather than HbA1c. Continuous glucose monitoring may be particularly valuable during pregnancy for women with pre-existing diabetes and hemoglobin variants.

Pediatric Patients

Children with diabetes and hemoglobin variants face lifelong challenges with glycemic monitoring. Early identification of hemoglobin variants through newborn screening programs provides an opportunity to establish appropriate monitoring strategies from the time of diabetes diagnosis.

Pediatric patients may benefit particularly from CGM technology, which provides detailed glucose information without reliance on HbA1c and can help children and families understand the relationship between food, activity, and glucose levels. The data from CGM can guide treatment decisions more effectively than potentially inaccurate HbA1c values.

Patients with Chronic Kidney Disease

Chronic kidney disease (CKD) adds another layer of complexity to HbA1c interpretation. Carbamylated Hb in patients with renal failure can affect the accuracy of HbA1c measurements. When CKD coexists with hemoglobin variants, HbA1c becomes even less reliable.

For patients with both CKD and hemoglobin variants, alternative monitoring strategies are essential. Glycated albumin may be particularly useful in this population, though it too can be affected by proteinuria in advanced kidney disease. CGM provides direct glucose measurement unaffected by either kidney disease or hemoglobin variants.

Patients with Other Hemolytic Conditions

Any condition that affects red blood cell lifespan can interfere with HbA1c accuracy. This includes not only hemoglobin variants but also conditions such as hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency, autoimmune hemolytic anemia, and mechanical hemolysis from prosthetic heart valves.

Patients with these conditions require the same careful approach to glycemic monitoring as those with hemoglobin variants, with consideration of alternative biomarkers and glucose-based monitoring methods.

Addressing Health Disparities

The intersection of hemoglobin variants and diabetes testing has important implications for health equity. Populations with high prevalence of hemoglobin variants, particularly African Americans, may experience systematic bias in diabetes diagnosis and management if the limitations of HbA1c testing are not recognized and addressed.

The findings suggest the common blood sugar test may be missing diabetes diagnoses in patients with the trait, which affects up to 10 percent of African-Americans. This systematic underdiagnosis could contribute to health disparities, with delayed treatment leading to increased complications and worse outcomes.

Healthcare systems must ensure that awareness of HbA1c limitations in patients with hemoglobin variants is widespread among providers and that appropriate alternative testing is readily available and covered by insurance. Quality metrics for diabetes care should account for the use of alternative monitoring methods in patients with hemoglobin variants, rather than penalizing providers who appropriately use methods other than HbA1c.

Research studies should routinely collect information about hemoglobin variant status and analyze results separately for affected populations to ensure that findings are applicable across diverse groups. Clinical practice guidelines should explicitly address monitoring strategies for patients with hemoglobin variants.

Practical Implementation Guide for Healthcare Providers

Healthcare providers can implement the following practical steps to ensure accurate glycemic monitoring for all patients:

Initial Assessment

• Obtain detailed family history and ethnic background for all patients with diabetes
• Consider hemoglobin variant screening for patients of African, Mediterranean, Middle Eastern, or Southeast Asian ancestry
• Review any previous hemoglobin electrophoresis or newborn screening results
• Assess for other conditions that may affect HbA1c accuracy (anemia, kidney disease, liver disease)

Ongoing Monitoring

• Always correlate HbA1c with other measures of glycemic control
• Investigate any discrepancies between HbA1c and glucose measurements
• For patients with known hemoglobin variants, use alternative monitoring methods or HbA1c methods without interference
• Document hemoglobin variant status prominently in the medical record
• Educate patients about the limitations of HbA1c in their specific situation

When to Use Alternative Methods

• Known hemoglobin variant with documented interference on the available HbA1c method
• Persistent discrepancy between HbA1c and glucose measurements
• Conditions affecting red blood cell lifespan (hemolytic anemia, recent blood transfusion, chronic kidney disease)
• Pregnancy in patients with hemoglobin variants
• Situations requiring short-term assessment of glycemic changes

Communication with Laboratory

• Know which HbA1c method your laboratory uses
• Understand the method's limitations with common hemoglobin variants
• Request hemoglobin variant screening when indicated
• Consult with laboratory medical director when results are questionable
• Advocate for alternative testing methods when needed

Resources for Healthcare Providers and Patients

Several organizations provide valuable resources for understanding and managing the challenges of HbA1c testing in patients with hemoglobin variants:

The National Glycohemoglobin Standardization Program (NGSP) maintains comprehensive information about HbA1c testing methods and their performance with various hemoglobin variants. Their website includes detailed tables showing which methods are affected by specific variants, helping laboratories and clinicians make informed decisions about testing approaches. Visit https://ngsp.org for current information.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides patient education materials about diabetes testing in people with hemoglobin variants, available in multiple languages. These resources can help patients understand why alternative testing may be necessary and what to expect.

Professional organizations including the American Diabetes Association, the Endocrine Society, and the American Association for Clinical Chemistry provide clinical practice guidelines and educational resources addressing glycemic monitoring in special populations.

Patient advocacy organizations for sickle cell disease and other hemoglobinopathies can provide support and education for individuals managing both diabetes and hemoglobin disorders.

Conclusion

The Hemoglobin A1c test remains an invaluable tool for diabetes management, providing a convenient and reliable measure of long-term glycemic control for most patients. However, its limitations in patients with hemoglobin variants represent a significant challenge that requires awareness, vigilance, and appropriate use of alternative monitoring strategies.

The accuracy of several HbA1c methods can be affected adversely by the presence of hemoglobin variants. The accuracy of HbA1c methods can be affected adversely by the presence of hemoglobin (Hb) variants or elevated levels of fetal hemoglobin (HbF). This interference can lead to misdiagnosis, inappropriate treatment decisions, and potentially worse outcomes for affected patients.

Healthcare providers must maintain a high index of suspicion for HbA1c interference in at-risk populations and be prepared to use alternative monitoring methods when necessary. This places emphasis on the limitations of HbA1c as a diagnostic and monitoring tool in patients with underlying hemoglobinopathies and highlights the importance of integrating alternative glycemic assessments in select populations.

The availability of alternative biomarkers including fructosamine and glycated albumin, along with advancing technologies such as continuous glucose monitoring and mass spectrometry, provides viable options for accurate glycemic assessment in patients with hemoglobin variants. As these technologies become more accessible and affordable, the challenges posed by hemoglobin variant interference may diminish.

Addressing this issue requires coordinated efforts from multiple stakeholders. Laboratories must select appropriate testing methods and clearly communicate limitations to clinicians. Healthcare providers must be educated about the potential for interference and know when to suspect and investigate discrepancies. Healthcare systems must ensure that alternative testing methods are available and covered by insurance. Researchers must continue developing improved testing technologies and studying the optimal approaches for diverse populations.

Most importantly, patients with hemoglobin variants must be recognized as a special population requiring individualized monitoring strategies. By acknowledging the limitations of HbA1c testing and implementing appropriate alternatives, we can ensure that all patients with diabetes receive accurate assessment and optimal care, regardless of their hemoglobin genotype.

The intersection of diabetes and hemoglobin variants highlights the importance of personalized medicine and the need to move beyond one-size-fits-all approaches to disease management. As our understanding of genetic diversity and its impact on diagnostic testing continues to grow, we must remain committed to developing and implementing testing strategies that work for all patients, ensuring health equity and optimal outcomes across diverse populations.